Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of DiaPep277 in newly diagnosed type 1 diabetes
2005-002590-73Phase 3Completed
- Sponsor
- Andromeda Biotech Ltd.
- Start
- Oct 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing DiaPep277 plus intensive insulin therapy with Placebo plus intensive insulin therapy (2 arms). Primary endpoint: Change from baseline in glucagon-stimulated C-peptide AUC secretion at 24 months. Started Oct 2005; status: completed.
02
Drugs
diapep277
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2005-002590-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002590-73.